Business Wire

Incheon City Takes off as Culture and Tourism Industry Hub in Northeast Asia with IFEZ’s Yeongjong Resort Complex Cluster

Share

With rich tourism infrastructure and resources, including the world’s top-level Incheon International Airport, Ganghwa Island, open port area, and multiple islands, the Incheon Metropolitan City government plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005029/en/

Incheon City plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project. Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities. The first resort complex in Korea, the Paradise City comprises a 5-star hotel, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons opened in 2017. To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment. It will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool. Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment to open in 2022. (Photo: Business Wire)

Incheon City plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project. Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities. The first resort complex in Korea, the Paradise City comprises a 5-star hotel, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons opened in 2017. To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment. It will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool. Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment to open in 2022. (Photo: Business Wire)

Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities, such as luxurious 5-star hotels, foreigners-only casinos, convention installations, spas, theme parks and more.

Having opened in April 2017 as the first resort complex in Korea, the ‘Paradise City’ comprises a 5-star hotel with 711 rooms, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons. From September 2018, it has been operating a boutique hotel with 58 suite rooms, spa blended with Korean dry sauna culture, the largest recreation club in Northeast Asia, and an art exhibition space. In March 2019, it opened the Wonder Box, an indoor theme park with the concept of ‘amusement park in the evening’, presenting enjoyment both to foreign and local visitors.

To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment headquartered in Las Vegas. The Caesars Resort Complex will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool.

Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment (MGE), the owner of Mohegan Sun casino located in Connecticut, to open in 2022. The resort complex will include a luxury hotel with over 1,250 rooms, foreigners-only casino, and indoor and outdoor theme parks. It will also operate a performing facility (arena) that can accommodate 15,000 audiences, staging Las Vegas-level fantastic performances all year round. It is expected to significantly contribute to spreading the Korean Wave.

The Incheon Free Economic Zone Authority expects the resort complex businesses to generate over 20,000 new jobs and production inducement effect of approximately KRW2 trillion (USD1680 million) annually. It also expects that the resort complex industry will conspicuously contribute to invigorating the regional economy and development of the MICE industry.

Contact information

Incheon Metropolitan City
Sang Kon Park
+82 32-440-3052
sangkon7@korea.kr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom